

1 114  
# 2  
BT  
6-13-02

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simon F. Williams, David P. Martin, and Frank A. Skraly

Serial No.: 10/082,954

Art Unit: Not Yet Assigned

Filed: February 26, 2002

Examiner: Not Yet Assigned

For: *MEDICAL DEVICES AND APPLICATIONS OF POLYHYDROXYALKANOATE  
POLYMERS*

Assistant Commissioner for Patents  
Washington, D.C. 20231

COPY OF PAPERS  
ORIGINALLY FILED

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the documents cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
EPA 0 452 111	10-16-1991	Takeda Chemical Industries	EP

RECEIVED  
JUN 0 6 2002  
TC 1700

### Publications

FRASER, et al., "Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant-reversible suppression of the menstrual cycle in the macaque," *Acta Endocrinol* 121:841-848 (1989).

HOLMES, et al., "Applications of PHB—a microbially produced biodegradable thermoplastic," *Phys Technol* 16:32-36 (1985).

KORSATKO, et al., "The influence of the molecular weight of poly-D(-)-3-hydroxybutyric acid on its use as a retard matrix for sustained drug release," *8<sup>th</sup> Europ. Congress of Biopharmaceutics and Pharmacokinetics* 1:234-242 (1987).

MODELLI, et al., "Kinetics of aerobic polymer degradation in soil by means of the ASTM D 5988-96 standard method," *J Environ Polym Degr* 7:109-116 (1999).


RENSTAD, et al., "The influence of processing induced differences in molecular structure on the biological and non-biological degradation of poly (3-hydroxybutyrate-co-3-hydroxyvalerate), P(3-HB-co-3-HV)," *Polymer Degradation and Stability* 63:201-211 (1999).

U.S.S.N.: 10/082,954  
Filed: February 26, 2002  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



---

Patrea L. Pabst  
Reg. No. 31,284

Dated: May 14, 2002


HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8500  
FAX 404-817-0470  
www.hklaw.com

U.S.S.N.: 10/082,954  
Filed: February 26, 2002  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

**Certificate of Mailing under 37 CFR §1.8(a)**

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 14, 2002

  
\_\_\_\_\_  
Kimberly L. Adams

ATL1 #524019 v1

to respond to a collection of information from the public that has been designated as "burdensome" by the Patent & Trademark Office.

**Complete if Known**

(use as many sheets as necessary)

10/082,954

February 26, 2002

**Simon F. Williams**

--	--

--	--

MBX 035 DIV
-------------

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Date Considered
-----------------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/082,954
				Filing Date	February 26, 2002
				First Named Inventor	Simon F. Williams
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	MBX 035 DIV

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		FRASER, et al., "Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant-reversible suppression of the menstrual cycle in the macaque," <i>Acta Endocrinol</i> 121:841-848 (1989).	
		HOLMES, et al., "Applications of PHB—a microbially produced biodegradable thermoplastic," <i>Phys Technol</i> 16:32-36 (1985).	
		KORSATKO, et al., "The influence of the molecular weight of poly-D(-)-3-hydroxybutyric acid on its use as a retard matrix for sustained drug release," <i>8<sup>th</sup> Europ. Congress of Biopharmaceutics and Pharmacokinetics</i> 1:234-242 (1987).	
		MODELLI, et al., "Kinetics of aerobic polymer degradation in soil by means of the ASTM D 5988-96 standard method," <i>J Environ Polym Degr</i> 7:109-116 (1999).	
		RENSTAD, et al., "The influence of processing induced differences in molecular structure on the biological and non-biological degradation of poly (3-hydroxybutyrate-co-3-hydroxyvalerate), P(3-HB-co-3-HV)," <i>Polymer Degradation and Stability</i> 63:201-211 (1999).	

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
JUN 06 2002  
TC 1700

Examiner's Signature		Date Considered	
-------------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

